<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00939913</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#2006.212.A</org_study_id>
    <nct_id>NCT00939913</nct_id>
  </id_info>
  <brief_title>Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy</brief_title>
  <acronym>NAC</acronym>
  <official_title>N-Acetylcysteine to Prevent Contrast-Induced Nephropathy in Acute Coronary Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cumberland Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ochsner Health System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients undergoing coronary angiography, the incidence of contrast induced
      nephropathy(CIN)varies widely and ranges from &lt; 5% in the lowest risk patients, to nearly 50%
      in the highest risk patients. Prior data has shown oral n-acetyl cysteine (NAC) to be
      effective in reducing the incidence of CIN.Due to extensive first pass metabolism, the
      bioavailability of oral NAC is poor and ranges from 4%-10%. We hypothesize that the incidence
      of CIN will be reduced in patients with ACS who undergo PCI by the prophylactic
      administration of intravenous NAC.

      This is a prospective, randomized, double-blind, placebo-controlled single center clinical
      trial designed to evaluate the effects of intravenous NAC on patients with acute coronary
      syndromes (ACS)undergoing coronary angiography and/or percutaneous coronary intervention
      (PCI). The medication Acetadote is provided by Cumberland Pharmaceuticals Inc
      (www.cumberlandpharma.com).

      Patients will be excluded if they have end-stage renal disease requiring dialysis,known
      hypersensitivity to NAC or a history of life-threatening contrast reaction. Primary end-point
      is incidence of CIN. Secondary end-points are in-hospital mortality,30-day mortality,duration
      of hospitalization and change in serum cystatin C level.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">May 2010</completion_date>
  <primary_completion_date type="Anticipated">May 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of CIN</measure>
    <time_frame>48-72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>in-hospital mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 day mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of hospitalization</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum cystatin C</measure>
    <time_frame>48-72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Nephropathy</condition>
  <arm_group>
    <arm_group_label>intravenous N-acetlycysteine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)as compared to placebo
Acetadote provided by Cumberland Pharmaceuticals Inc.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous NAC</intervention_name>
    <description>intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)</description>
    <arm_group_label>intravenous N-acetlycysteine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 years of age or older.

          2. Hospitalized with a primary diagnosis of acute coronary syndrome.

          3. Scheduled for coronary angiography or intervention during the current hospitalization.

        Exclusion Criteria:

          1. Have end-stage renal disease (ESRD) requiring dialysis.

          2. Have a known hypersensitivity to NAC.

          3. Have a history of life-threatening contrast reaction. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Arthur Grant, MD</last_name>
    <phone>(504) 842-6281</phone>
    <email>agrant@ochsner.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zehra Jaffery, MD</last_name>
    <phone>504-842-7157</phone>
    <email>zjaffery@ochsner.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arthur G Grant, MD</last_name>
      <phone>504-842-6281</phone>
      <email>agrant@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Arthur G Grant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 15, 2009</study_first_posted>
  <last_update_submitted>September 17, 2009</last_update_submitted>
  <last_update_submitted_qc>September 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Arthur G. Grant MD</name_title>
    <organization>Ochsner medical center</organization>
  </responsible_party>
  <keyword>contrast nephropathy</keyword>
  <keyword>intravenous n-acetlycysteine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

